Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Ischemia-Reperfusion Lung Injury in Lung Transplant
NCT00060450Phase 3Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Aug 2001
- Primary completion
- Sep 2006
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemia-reperfusion injury (IRI) comparing Inhaled Nitric Oxide with Placebo (2 arms). Primary endpoints: Arterial and mixed venous blood gases and Pulmonary vascular pressures. Started Aug 2001; status: terminated.
02
Drugs
nitric oxide
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00060450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060450.